Global Intravenous Iron Drugs Market 2017-2021

  • ID: 4201989
  • Report
  • Region: Global
  • 70 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 6

FEATURED COMPANIES

  • Allergan
  • AMAG Pharmaceuticals
  • Daiichi Sankyo
  • Galenic
  • Nippon Shinyaku
  • NOXXON Pharm
  • MORE
About IV Iron Drugs

Iron is one of the most important minerals in the human body. One of the major components of hemoglobin, iron helps the blood carry oxygen. Iron deficiency can affect the production of hemoglobin and cause anemia. This condition is known as iron deficiency anemia.

The analysts forecast the global IV iron drugs market to grow at a CAGR of 10.46% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global IV iron drugs market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of IV iron drugs.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

The report, Global IV Iron Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market.

Key vendors
- Allergan
- AMAG Pharmaceuticals
- Daiichi Sankyo
- Galenica
- Pharmacosmos

Other prominent vendors
- Nippon Shinyaku
- NOXXON Pharma
- Rockwell Medical
- Sanofi
- Wanbang Biopharmaceutical

Market drivers
- Growing demand for non-dextran intravenous iron drugs
- For a full, detailed list, view the full report

Market challenges
- Presence of substitutes coupled with growing research activities for new alternatives
- For a full, detailed list, view the full report

Market trends
- Increase in favorable guidelines from healthcare organizations
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the Key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Allergan
  • AMAG Pharmaceuticals
  • Daiichi Sankyo
  • Galenic
  • Nippon Shinyaku
  • NOXXON Pharm
  • MORE
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
  • Key market highlights
PART 05: An overview of iron deficiency

PART 06: Pipeline landscape

PART 07: Market landscape
  • Market overview
  • Five forces analysis
PART 08: Market segmentation by product type
  • Ferric carboxymaltose
  • Sucrose
  • Dextran
  • Others
PART 09: Geographical segmentation
  • Intravenous iron drugs market in Americas
  • Intravenous iron drugs market in EMEA
  • Intravenous iron drugs market in APAC
PART 10: Decision framework

PART 11: Drivers and challenges
  • Market drivers
  • Impact of drivers on key customer segments
  • Market challenges
  • Impact of challenges on key customer segments
PART 12: Market trends
  • Increase in favorable guidelines from healthcare organizations
  • Increasing strategies of vendors to expand reach of intravenous iron drugs
  • Growing focus on emerging economies
PART 13: Vendor landscape
  • Competitive scenario
PART 14: Key vendor analysis
  • Allergan
  • AMAG Pharmaceuticals
  • Daiichi Sankyo
  • Galenica
  • Pharmacosmos
  • Other prominent vendors
PART 15: Appendix
  • List of abbreviation
List of Exhibits
Exhibit 01: Pipeline landscape
Exhibit 02: Global intravenous iron drugs market
Exhibit 03: Annual shipment sales growth of Ferinject/Injectafer in key countries in 2015
Exhibit 04: Global intravenous iron drugs market 2016-2021 ($ millions)
Exhibit 05: Global intravenous iron drugs market: Opportunity analysis
Exhibit 06: Five forces analysis
Exhibit 07: Market segmentation by product type 2016
Exhibit 08: Ferric carboxymaltose-based intravenous iron drugs market 2016-2021 ($ millions)
Exhibit 09: Global sucrose-based intravenous iron drugs market 2016-2021 ($ millions)
Exhibit 10: Global dextran-based intravenous iron drugs market 2016-2021 ($ millions)
Exhibit 11: Global other intravenous iron drugs market 2016-2021 ($ millions)
Exhibit 12: Global intravenous iron drugs market by geography 2016 and 2021
Exhibit 13: Global intravenous iron drugs market by geography: Revenue 2016-2021 ($ millions)
Exhibit 14: Market scenario in Americas
Exhibit 15: Intravenous iron drugs market in the Americas 2016-2021 ($ millions)
Exhibit 16: Market scenario in EMEA
Exhibit 17: Intravenous iron drugs market in EMEA 2016-2021 ($ millions)
Exhibit 18: Market scenario in APAC
Exhibit 19: Intravenous iron drugs market in APAC 2016-2021 ($ millions)
Exhibit 20: Impact of drivers
Exhibit 21: Cost comparison of key drugs per week 2015 ($)
Exhibit 22: Cost comparison of key drugs per treatment 2015 ($)
Exhibit 23: Impact of challenges
Exhibit 24: Competitive structure analysis of global intravenous iron drugs market 2016
Exhibit 25: Market share analysis 2016
Exhibit 26: Competitive analysis of global intravenous iron drugs market
Exhibit 27: Strategic success factors of companies in global intravenous iron drugs market
Exhibit 28: Allergan: Strength assessment
Exhibit 29: Allergan: Strategy assessment
Exhibit 30: Allergan: Opportunity assessment
Exhibit 31: AMAG Pharmaceuticals: Key highlights
Exhibit 32: AMAG Pharmaceuticals: Strength assessment
Exhibit 33: AMAG Pharmaceuticals: Strategy assessment
Exhibit 34: AMAG Pharmaceuticals: Opportunity assessment
Exhibit 35: AMAG Pharmaceuticals: YoY revenue and growth rate of Feraheme ($ millions)
Exhibit 36: Daiichi Sankyo: Key highlights
Exhibit 37: Daiichi Sankyo: Strength assessment
Exhibit 38: Daiichi Sankyo: Strategy assessment
Exhibit 39: Daiichi Sankyo: Opportunity assessment
Exhibit 40: Daiichi Sankyo: YoY revenue and growth rate of Injectafer 2013-2015 ($ millions)
Exhibit 41: Daiichi Sankyo: YoY revenue and growth rate of Venofer 2013-2015 ($ millions)
Exhibit 42: Galenica: Key highlights
Exhibit 43: Galenica: Strength assessment
Exhibit 44: Galenica: Strategy assessment
Exhibit 45: Galenica: Opportunity assessment
Exhibit 46: Galenica: YoY revenue and growth rate of Ferinject 2013-2015 ($ millions)
Exhibit 47: Galenica: YoY revenue and growth rate of Venofer 2013-2015 ($ millions)
Exhibit 48: Pharmacosmos: Key highlights
Exhibit 49: Pharmacosmos: Strength assessment
Exhibit 50: Pharmacosmos: Strategy assessment
Exhibit 51: Pharmacosmos: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Allergan
  • AMAG Pharmaceuticals
  • Daiichi Sankyo
  • Galenic
  • Nippon Shinyaku
  • NOXXON Pharm
  • MORE
New Report Released: – Global IV Iron Drugs Market 2017-2021

The author of the report recognizes the following companies as the key players in the global IV iron drugs market: Allergan, AMAG Pharmaceuticals, Daiichi Sankyo, Galenica, and Pharmacosmos

Other Prominent Vendors in the market are: Nippon Shinyaku, NOXXON Pharma, Rockwell Medical, Sanofi, and Wanbang Biopharmaceutical

Commenting on the report, an analyst from the research team said: “Favorable guidelines from healthcare organizations will likely drive the adoption rates of intravenous iron drugs. For instance, in May 2016, the European Society of Cardiology posted guidelines for the diagnosis and treatment of acute and chronic heart failure. These guidelines strongly recommend Ferinject for the treatment of iron deficiency in patients with systolic heart failure. The guidelines also stated that treatment of these individuals with Ferinject for up to one year showed reduced hospitalization rates. In addition, in February 2015, Ferinject was presented at the European Crohn’s and Colitis Organization congress, which posted guidelines on the diagnosis and management of iron deficiency and anemia in individuals with irritable bowel syndrome. These new guidelines recommended intravenous iron as a first line therapy for specific patients. Also, in 2014, Norfolk and Norwich University Hospitals released a trust guideline for the management and administration of intravenous iron in adults, mandating the use of Venofer and Ferinject for individuals with irritable bowel syndrome or other gastrointestinal conditions. These drugs are indicated in individuals who are intolerant or non-responsive to oral iron drugs. It also includes patients with iron deficiency anemia under the supervision of gastroenterologist. Such guidelines will improve the adoption rates of intravenous iron drugs.”

According to the report, the market has witnessed a shift from conventional dextran intravenous iron drugs to non-dextran intravenous iron drugs. The increased demand for these drugs is attributed to their ability to deliver larger doses of iron in a short time. Furthermore, ferric carboxymaltose is preferred over iron polymaltose for outpatients as it can be managed easily. Injectafer/Ferinject is the first non-dextran product indicated for the treatment of anemia. This drug is manufactured and marketed by Galenica (outside the US and Canada) and Daiichi Sankyo (the US and Canada). Galenica's Ferinject reported sales of $261.14 million in 2015, indicating an increase of 26.8% over that in previous fiscal year. Daiichi Sankyo's Injectafer posted sales of $155 million in 2015, reflecting a YoY growth of 124.6%. Injectafer/Ferinject addresses challenges such as intolerance or unsatisfactory response, safety concerns, and dosing and compliance issues associated with conventional iron therapies. Injectafer/Ferinject contains ferric carboxymaltose, which is a stable complex and possesses very low immunogenic potential. Therefore, it does not pose the risk of anaphylactic reactions. Furthermore, these drugs allow the administration of large doses in a single and rapid session without the requirement of a test dose. Such advantages will drive the adoption of non-dextran therapies for the treatment of anemia.

Further, the report states that the preference for alternatives to intravenous iron drugs has increased owing to rising need to reduce the side effects. Some substitutes include iron supplements, which are usually prescribed for people at risk of developing anemia, such as pregnant women. Iron supplements can also be used by individuals with anemia. In addition, individuals are turning to iron-rich foods, which reduces the need to take iron drugs or other supplements in the future. For instance, chicken liver, seafood such as oysters and clams, beef, and turkey provides large amounts of iron. Also, some of the vegetables such as lentils, spinach, and beans contain non-heme iron. In addition, the adoption of herbal remedies to boost the absorption of iron and other nutrients has also been increasing. The University of Maryland Medical Center states that dandelion, alfalfa, burdock, and yellow dock can be used to help cleanse the blood and enhance the levels of hemoglobin. In addition, growing research activities to develop and introduce alternative therapies will hinder the growth prospects of the market. For instance, in June 2016, Shield Therapeutics launched Feraccru for the treatment of iron deficiency anemia in individuals with irritable bowel disease. Shield Therapeutics claims that Feraccru could become an alternative to intravenous iron drugs as they pose complications such as allergic reactions, iron overload, and high overall cost. On the other hand, Feraccru offers simple oral administration, efficient absorption, and rapid effect like intravenous drugs. Furthermore, it is more cost-effective than intravenous drugs. Such research studies will hamper the growth prospects of the market.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 6
  • Allergan
  • AMAG Pharmaceuticals
  • Daiichi Sankyo
  • Galenic
  • Pharmacosmos
  • Nippon Shinyaku
  • NOXXON Pharm
  • Rockwell Medical
  • Sanofi
  • Wanbang Biopharmaceutical
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll